This filing is administrative and contains no new financial data or guidance. Monitor next quarterly report for any operational updates or pipeline catalysts. The equity plan increase is a non-event for near-term trading.
OCUL drugs
OCUL drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 15 $8.99entry
- T+1 · 5mo ago −0.56%α +0.04% · $8.94
- T+5 · 5mo ago +10.90%α +12.28% · $9.97
- T+20 · 4mo ago +9.90%α +10.65% · $9.88
- T+60 · 2mo ago +27.59%α +26.58% · $11.47
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Ocular Therapeutix filed an 8-K reporting the formal appointment of Jason Robins as CFO (previously interim) and stockholder approval of a 10,000,000-share increase to the 2021 Stock Incentive Plan at the 2026 Annual Meeting. The CFO appointment is a routine transition with no red flags, and the equity plan increase is standard for a biotech. No material financial data or guidance was provided.
Key Facts
- Jason Robins appointed CFO on June 10, 2026, after serving as interim CFO since January 20, 2026.
- Robins' annual base salary increased to $535,100 effective July 1, 2026, with a target bonus of 45% of base salary.
- Robins received a stock option for 14,024 shares and an RSU award for 15,441 shares, both subject to vesting.
- Stockholders approved Amendment No. 5 to the 2021 Stock Incentive Plan, increasing authorized shares by 10,000,000.
- All five stockholder proposals at the 2026 Annual Meeting passed, including election of directors and ratification of PwC as auditor.
Financial Impact
No material financial impact. CFO compensation is routine; equity plan increase of 10M shares is standard for ongoing incentive compensation.
Risk Factors
- Potential dilution from 10M additional shares under the equity plan, though typical for a biotech of this size.
- No financial results or guidance provided in this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-073496 |
| Document: 0001104659-26-073496-index-headers.html | 0001104659-26-073496 |
| Document: 0001104659-26-073496-index.html | 0001104659-26-073496 |
| Document: 0001104659-26-073496.txt | 0001104659-26-073496 |
Track record
20 reports on OCUL
4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +24.88% at T+20 after the Aug 3, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 10, 20266d ago 3 Neutral 2/10 Entry $6.66 Now $6.01 −9.76% settles Nov 18
- Nov 9, 20267d ago 8-K Neutral 2/10 Entry $6.85 to $6.01 Now $6.01 −12.26% ▼ −12.26% −10.57% vs SPY
- Nov 9, 20267d ago Press Release Bearish 5/10 Entry $6.85 to $6.01 Now $6.01 +12.26% ▲ +12.26% +10.57% vs SPY
- Nov 5, 202611d ago 144 Neutral 3/10 Entry $6.60 to $6.21 Now $6.01 −8.87% ▼ −5.84% −8.43% vs SPY
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $6.29 to $6.47 Now $6.01 −4.45% ▲ +2.86% +3.01% vs SPY
- Oct 8, 20265w ago 144 Neutral 2/10 Entry $7.54 to $6.87 Now $6.01 −20.29% ▼ −8.89% −6.92% vs SPY
- Sep 2, 202610w ago Insider Cluster Neutral 4/10 Entry $10.64 to $10.49 Now $6.01 −43.52% ▼ −1.41% −0.26% vs SPY
- Aug 26, 202611w ago Insider Cluster Neutral 3/10 Entry $10.82 to $10.64 Now $6.01 −44.45% ▼ −1.66% −1.93% vs SPY
- Aug 3, 202615w ago 8-K Bullish 7/10 Entry $8.40 to $9.24 Now $6.01 −28.45% ▲ +10.00% +7.97% vs SPY
- Jun 17, 202621w ago Press Release Bullish 6/10 Entry $9.64 to $9.85 Now $6.01 −37.66% ▲ +2.18% +3.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers